Arkolith/Insider Trading/ZNTL/Form 4

Blackwell Kimberly

Chief Executive Officer, DirectorZentalis Pharmaceuticals, Inc. (ZNTL) · full profile →Form 4 · filed Feb 5, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 1, 2024Grant(A)250K—$0505K
Feb 1, 2024Tax withholding(F)21K$11.69$241K484K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 1, 2024Grant(A)250K—$0250K

Transaction Codes

A
Grant / award
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001725160-24-000026) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML